Gianni Faedda
Psychiatry · New York, NYNPI 1477609931
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,675 of the $5,441 with a category attached, or 67.5%. Neurocrine Biosciences, Inc. accounts for 63.1% of it on its own, with 6 other manufacturers making up the rest. 2023 is the largest year on record at $3,250, 2.0 times the $1,613 reported in 2019. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 15 payments — averaging $362.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$3K
- Sunovion Pharmaceuticals Inc.$828
- Alkermes, Inc.$452
- Avanir Pharmaceuticals, Inc.$425
- Otsuka America Pharmaceutical, Inc.$250
- AbbVie$30
- plus $24 from 1 others
Across 55 payments — averaging $4030.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neurocrine Biosciences, Inc.$95K
- Teva Pharmaceuticals USA, Inc.$59K
- AbbVie$41K
- Acadia Pharmaceuticals Inc$9K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$5K
- Sunovion Pharmaceuticals Inc.$4K
- plus $8K from 3 others
What the payments were for
- Consulting fees$3,67568%
- Speaking & faculty fees$82815%
- Food & beverage$93917%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 4 | $3,432 |
| Sunovion Pharmaceuticals Inc. | 2 | $828 |
| Alkermes, Inc. | 4 | $452 |
| Avanir Pharmaceuticals, Inc. | 1 | $425 |
| Otsuka America Pharmaceutical, Inc. | 2 | $250 |
| AbbVie | 1 | $30 |
| Lundbeck LLC | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$1,458
- LATUDA$828
- ARISTADA INITIO$365
- REXULTI$250
- INGREZZA$102
How this compares
$5,441 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClozarilClozapine | 68 | $10,037 |
| RitalinMethylphenidate Hcl | 12 | $2,425 |
| Ziprasidone Hcl | 14 | $231 |
| Lithium Carbonate ErLithium Carbonate | 17 | $211 |
| Risperidone | 14 | $101 |
| Lorazepam | 15 | $98 |
| Zolpidem Tartrate | 11 | $77 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in New York
- Manish ZinzuvadiaNew York$1.3M
- Jianping ChenNew York$1.2M
- Ulla Kristina LaaksoNew York$890K
- Kerry SulkowiczNew York$435K
- Ralph AquilaNew York$143K
- Daniel KarlinNew York$101K
- David StraussNew York$95K
- Anissa Abi-DarghamNew York$94K
- Robin McGarryNew York$69K
- Nicole AllenNew York$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.